Highlighting KALA BIO's Innovative Approach
KALA BIO, Inc., a pioneering biopharmaceutical entity focused on advancing therapies for serious ocular conditions, is set to host a compelling webcast event featuring prominent Key Opinion Leaders (KOLs). The highlight of the event will concentrate on KPI-012, a therapeutic solution aimed at addressing persistent corneal epithelial defect (PCED). As a clinical-stage company, KALA BIO continues to showcase its commitment to addressing critical healthcare needs.
Event Details and Key Presenters
The webcast is scheduled for Wednesday, at 4:00 PM ET, where attendees will have the unique opportunity to hear from leading experts in the ophthalmology field. Noteworthy speakers include:
Expert Insights from Ophthalmology Leaders
Francis Mah, M.D., an esteemed Director at Scripps Clinic, will provide valuable perspectives on corneal diseases. Also presenting is Anthony Aldave, M.D., who holds a Professorship at Jules Stein Eye Institute and specializes in corneal and uveitis cases.
Dr. Stephen Pflugfelder from Baylor College of Medicine will share his expertise, along with Melissa Toyos, M.D., a significant voice from Toyos Clinic. Each speaker will illuminate the pressing unmet needs in PCED and how KPI-012 is positioned to address these challenges.
Understanding the Potential of KPI-012
During the event, participants can expect a comprehensive overview of PCED and the innovative mechanisms behind KPI-012. Todd Bazemore, interim Chief Executive Officer at KALA BIO, will present a detailed analysis of the commercial landscape and milestones related to KPI-012.
A Q&A Session to Engage Participants
Following the presentations, attendees will have an opportunity to engage in a Q&A session, fostering meaningful dialogue surrounding the topics discussed. This interactive approach aims to enhance understanding and interest in the developments concerning KPI-012.
About KPI-012 and Its Significance
KPI-012 represents a groundbreaking investigational therapy designed for patients suffering from PCED, a condition marked by impaired corneal healing. KALA BIO’s MSC-S platform underpins this product, leveraging the benefits of human-derived biofactors, including growth factors and neurotrophic factors that play a pivotal role in corneal regeneration.
The FDA has recognized the significance of KPI-012 by granting it Orphan Drug and Fast Track designations, which facilitate streamlined development processes in response to urgent medical needs.
Future Directions and Research Initiatives
In addition to its focus on persistent corneal epithelial defects, KALA is exploring a wider scope of applications for KPI-012, particularly in the realm of Limbal Stem Cell Deficiency and other rare ocular diseases that jeopardize vision. The company has not only initiated further preclinical studies but is also evaluating the potential use of its MSC-S platform in tackling retinal degenerative diseases like Retinitis Pigmentosa and Stargardt Disease.
How to Participate
Interested individuals are encouraged to register for the live webcast to gain insights into these innovative developments. A replay of the presentation will also be available afterward on KALA BIO's website.
Frequently Asked Questions
What is KPI-012?
KPI-012 is an investigational therapy developed by KALA BIO that aims to treat persistent corneal epithelial defects by promoting corneal healing.
When is the KOL event taking place?
The KOL event will occur on Wednesday at 4:00 PM ET.
Who are the speakers at the event?
Speakers include leading experts like Dr. Francis Mah, Dr. Anthony Aldave, Dr. Stephen Pflugfelder, and Dr. Melissa Toyos.
How can I attend the webcast?
You can register for the webcast through KALA BIO's official website.
What is the significance of KPI-012?
KPI-012 has received Orphan Drug and Fast Track designations, highlighting its potential to address critical patient needs in ocular health.
